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Introduction
The HER-2/neu oncogene (also called c-erbB-2) encodes a 185-kDa epidermal growth factor (EGF) receptor-related transmembrane protein (p185) with intrinsic tyrosine kinase activity. [1] [2] [3] Amplification and/or overexpression of the HER-2/neu proto-oncogene occurs in many human cancer cells, including approximately 30% of breast cancers and ovarian cancers, and correlates with poor prognosis and shorter survival. [4] [5] [6] [7] Because down-regulation of HER-2/neu is shown to be able to reverse the transformation of cancer cells, [8] [9] [10] [11] [12] HER-2/neu is thus considered an important target for cancer therapy. [12] [13] [14] [15] [16] [17] [18] This concept is supported by our previous finding that adenovirus 5 E1A repressed HER-2/neu transcription and consequently suppressed transformation and tumorigenicity induced by HER-2/neu overexpression in cancer cells. 10, [19] [20] [21] Thus, E1A has great potential for use in gene therapy to target the HER-2/neu-overexpressing human cancers.
In previous studies, we treated mice-bearing HER-2/neu-overexpressing tumor intraperitoneally with cationic liposome E1A complex. 15, 22 Expression of E1A protein in the tumor tissue decreased the p185 protein level and significantly prolonged survival of mice; about 70% of the treated mice survived longer than 1 year. Safety studies indicated that intraperitoneal (i.p.) administration of E1A-liposome complex at the effective dose did not produce significant toxicity in immunocompetent mice. 23 The E1A-liposome gene therapy protocol was thus approved by the Recombinant DNA Advisory Committee and the United States Food and Drug Administration for a phase I trial in patients with HER-2/neu-overexpressing breast and ovarian cancer.
E1A-liposome complex may become a valuable therapeutic agent for patients with HER-2/neu-overexpressing cancer. However, improvement of the E1A-liposome gene delivery system in clinical application is still needed. First, in the current clinical protocol, the E1A-liposome complex is formulated by 10 nmol of DOPE/DC-chol liposome complexed with 1 g of E1A. This dose was chosen since in in vitro tissue culture, the highest transfection efficiency can be reached by the complex of DOPE/DC-chol with E1A as 10 nmol of lipid with 1 g of DNA (10:1) (or as 13 nmol of lipid with 1 g of DNA (13:1)). 15, 22 However, the optimal transfection condition for tissue culture is not necessarily the best in in vivo experiments. It may be beneficial to use lower amounts of lipid in the complex while obtaining similar gene-transfer efficacy. Potential toxic effects from lipid will consequently be reduced, and a higher dosage of the DNA may be administrated if better effects can be achieved.
Another issue is posed by the adenovirus 5 E1A, a multiple functional protein involved in a variety of cellular events. E1A is capable of immortalizing primary culture cells and cooperates with ras or E1B oncogenes to transform them. 24, 25 In cancer patients, cells in non-tumor tissues may carry multiple genetic defects. 26 The nonspecific uptake of E1A might cause transformation in these non-tumor cells and consequently cause tumor cells to develop. The immortalization function of E1A is associated with its conserved region 2 (CR2) domain, which is necessary for binding and inactivation of RB. 27 The conserved region 3 (CR3) domain of E1A is associated with transactivation function that enhances expression of many cellular genes. [28] [29] [30] Mini-E1A, a deletion construct developed recently, does not contain the CR2 and CR3 domains, but still is capable of repressing HER-2/neu transcription and suppressing rat HER-2/neu-mediated transformation in mouse fibroblast. 31 Therefore, mini-E1A may be a more specific and safer therapeutic agent, if it suppresses tumor development in vivo as efficiently as the wild-type E1A.
The cationic liposome-DNA complex expresses transgene transiently in cells. However, it is not clear how long the trace amount of transgene stays inside the cells. Long-term persistence of the transgene might induce its integration into the chromosome of normal cells and cause genomic mutation, and its occurrence in the cells of reproductive organs is especially of concern. This is thus another issue in applying gene therapy strategies to cancer patients. The current study addresses all the issues mentioned above and will provide critical information for the design of future clinical trials.
Results
A DNA-liposome complex with a lower than standard lipid dose can transfer the gene with the same efficacy An E1A-liposome gene-delivery protocol as therapy for HER-2/neu-overexpressing cancer was previously developed by our laboratory. Adminstrating the E1A-liposome complex to mice bearing HER-2/neu-overexpressing tumors efficiently suppressed tumor development and significantly prolonged host survival. 15, 16 Safety studies also demonstrated that this complex has no adverse effects on the normal organs of mice, and it is currently being tested in a phase I clinical trial in patients with HER-2/neu-overexpressing cancers. However, the in vivo formulation of this E1A-liposome complex, which has cationic liposome and E1A in a ratio of 13 nmol to 1 g (13:1), was based on its transfection efficiency in cell culture in vitro. The optimum condition for DNA-liposome complex transfection on tumor cells may be different in vivo and in vitro. We therefore wished to examine further the gene-transfer efficiency of a series of DNAliposome complexes in vivo in ovarian cancer cells.
pCHC-␤-gal, an expression vector encoding ␤-galactosidase, 32 was used as a marker for gene transfer in vivo. The transfection efficacy of the pCHC-␤-gal-liposome complex was tested in an orthotopic ovarian cancer model, using a ratio of liposome (nmol) to DNA (g) of 26:1, 13:1, 10:1, 5:1, 1:1, 0.5:1 or 0:1. Each complex was injected i.p. daily for 3 consecutive days into a group of tumor-bearing mice, that 6 weeks earlier had been inoculated i.p. with 2 × 10 6 HER-2/neu-overexpressing SKOV-3.ip1 cells. Tumor nodules were analyzed for ␤-galactosidase activity by staining tumor sections or assaying the protein lysate. As shown in Figure 1a , the DNA-liposome complexes in ratios from 26:1 to as low as 1:1 had similar gene transfer efficacies, whereas the gene transfer ability of DNA alone was much lower than any of these (P Ͻ 0.025). Similar results were observed when the protein lysate was assayed for ␤-gal activity (Figure 1b) . These results indicated that cationic liposome was required for efficient DNA transfection of tumor cells in vivo, and a low amount of lipid, such as in a 1:1 ratio, might be sufficient to maintain a good gene expression. Based on these results, we hypothesized that a much lower amount of lipid might be sufficient for the E1A-liposome complex to obtain similar E1A gene-expression efficacy and therefore to reach tumor-suppression activity compared with that of the current E1A gene-delivery formulation.
To test the tumor-suppression activity of E1A-liposome complexes containing different lipid dosages, we examined the E1A-liposome complexes with 13:1 and 1:1 ratios in the orthotopic ovarian cancer animal model. Female nu/nu mice bearing established late-stage i.p. SKOV3.ip1 ovarian cancer were inoculated i.p. with E1A-liposome complexes of 13:1 and 1:1, or with phosphatebuffered saline (PBS). As a control, two more groups of female mice bearing i.p. tumors from another human ovarian cancer cell line 2774 c-10, which has basal level of HER-2/neu gene expression, were treated with E1A-liposome or Efs-liposome (a frame shift mutant of E1A that does not have tumor suppression effects on tumors from SKOV-3.ip cells (15)) complex at 13:1 ratio. Injections were performed three times per week for the first week then once per week until the 16th week, when all the mice in the PBS control groups or in the control 2774 c-10 groups had died. The survival rate of each group of mice is shown in Figure 2a and b.
Mice treated with PBS developed i.p. and metastatic tumors, and all died before the 16th week of treatment. The mice treated with the E1A-liposome complex at a 13:1 ratio survived significantly longer (E1A-13 versus PBS, P Ͻ 0.01). The treatment with E1A-liposome complex at a 1:1 ratio also prolonged mouse survival significantly (E1A-1 versus PBS, P Ͻ 0.01), and mouse survival duration of the E1A 1:1 complex was equivalent to or better than that of E1A in the 13:1 complex. These results demonstrated that the E1A-liposome complex with a low lipid ratio, which certainly has less potential adverse effects on the mice, still mediated similar therapeutic effects in our experimental system. This result was also confirmed by the experiment using mini-E1A construct (Figure 2c and in the next section, see also Figure 3a and b). Our data, therefore, strongly suggest that E1A-liposome complexes with a lipid content of 1:13 the original dose will have the same potential to suppress tumor development.
Mini-E1A has the same tumor suppression activity as wild-type E1A Ad 5 E1A is a multiple-function protein which is involved in many cellular events beside repressing HER-2/neu. It is beneficial in minimizing the E1A molecule to make it a more specific target agent for HER-2/neu gene expression and transformation. Mini-E1A (E1A N80) was identified, 31 which only contains the domains sufficient for repression of HER-2/neu and lacks the domain required for E1A-mediated immortalization (ie the CR2) and the domain for transactivation function (ie the CR3). Mini-E1A was shown to be as potent as the wild-type E1A in suppression of the HER-2/neu-mediated transformation in mouse fibroblast NIH3T3 cells, by comparison of transformation phenotypes among different stable transfectants of E1A and mini-E1A. 31 We therefore examined whether mini-E1A is able to suppress HER-2/neumediated tumor development in tumor-bearing mice through our established gene therapy protocol. In the same experimental system as shown in Figure 2a , administration of mini-E1A to the tumor-bearing mice significantly prolonged mouse survival by both the 13:1 and 1:1 complex (mini-E1A-13 versus PBS, P Ͻ 0.025; mini-E1A-1 versus PBS, P Ͻ 0.025) and the in vivo tumor suppression activity of mini E1A was as potent as wild-type E1A (Figure 3a and b) . The mini-E1A complexes at 13:1 and 1:1 ratio showed no differences in mediating tumor-suppression activity in our experimental condition ( Figure  2c) ; mini-E1A may therefore be substituted for E1A for more specific targeting of HER-2/neu-mediated transformation.
Long-term expression of the E1A gene in mouse organs Cationic liposome DNA is a delivery system that results in transient gene expression in cells; the DNA is degraded afterwards. However, we do not know how long the gene may stay in cells and whether it can be integrated into the chromosome in vivo. This is a critical concern of safety in gene therapy. The following analysis was performed to demonstrate whether the E1A gene still resides in normal cells after mice have survived for a certain period of time. Three mice, that were treated by E1A liposome (two from the 1:1 ratio group, one from the 13:1 ratio group) and had survived free of tumor for 1. years after the last E1A-liposome injection, were tested in this study. Major organs including uterus, ovaries, liver, lung, heart, kidney, spleen and brain were collected and their DNA was extracted. PCR was performed using a pair of primers that specifically amplify a fragment in E1A intron 1 and a second pair of primers for the mouse genomic growth-hormone gene as a control. 33 Figure 4a shows that, under our experimental conditions, E1A DNA was selectively detected in only the lungs of all three mice and the kidneys of two. The result was also confirmed by PCR of these DNA samples, using another pair of primers that amplify DNA in E1A intron 2, and the same result was obtained (data not shown). Therefore, E1A DNA exists only in mouse lung and kidney and not in most other organs examined 1. years after the last E1A-liposome i.p. administration. The lack of E1A DNA in ovaries by PCR is a significant observation as it strongly suggests that the germ cells will not carry the transgene under the protocol we used. Thus, the possibility of E1A gene transmission to the F1 offspring is unlikely.
The E1A DNA detected in the mouse organs could either be the residue of the injected E1A gene, or synthesized by mouse cell DNA replication after administration of E1A-liposome. E1A in the latter case is possibly integrated into the chromosome. We were interested in distinguishing these two possibilities by using a DNA restriction enzyme DpnI. DpnI digests DNA with sequence G m ATC but not with sequence GATC, ie it cleaves only the DNA synthesized in methylation-competent prokaryotic cells. The E1A intron sequence amplified by the PCR above has two GATC DpnI sites. Thus, the tissue DNA sample containing the bacterially derived E1A plasmid will not be detected by the PCR if it is pretreated with DpnI, because the bacterially derived E1A template will be fragmented by DpnI at G m ATC. If the E1A DNA is integrated into the chromosome, the DNA sample containing the mammary synthesized E1A will be PCR positive, because the E1A DNA is resistant to DpnI digestion. When we pretreated the DNA from the lungs and kidneys with DpnI and then performed PCR, the specific E1A bands were still detected ( Figure 4b ). As a control, 0.1 and 0.01 pg of bacterially derived E1A plasmid (the same batch used to inject the mice) was mixed with 0.5 g genomic DNA (approximately 20 and two copies of E1A plasmid in every mouse cell) from a mouse that was never treated with E1A, and subjected to PCR. Under the same PCR conditions, a PCR product of E1A was detected in the DpnI untreated mix DNA sample, however, no signal could be detected in the DpnI pretreated mix DNA (Figure 4c ). The plasmid E1A mixed with the cellular DNA can be digested in the presence of DpnI and thus was not detectable in our PCR conditions. The results suggest that the E1A detected in Figure 4b was most likely synthesized by the mouse cell and resistant to DpnI digestion. The results also suggest that the E1A DNA detected in lungs and kidneys was most likely integrated into chromosome of mouse cells.
Discussion
Cationic liposome has been proven to be a gene carrier with the advantages of easy use, low toxicity and transient gene expression. Several gene therapy clinical trials using a cationic liposome are ongoing. DOPE/DC-chol was used in some of them 34, 35 and achieved biological effects in patients without adverse effects. 34, 36 A phase I clinical trial of DOPE/DC-chol liposome-mediated E1A Cationic liposome complexes with DNA through charge interaction. Liposome protects DNA from degradation in the cells. Excess amounts of liposome result in the positive charge of the complex and may therefore help the attachment of the complex to the negatively charged cell surface. The complex of DNA-liposome at a 1:1 ratio is negatively charged, since DNA-liposome complex at 10:1 theoretically has the (±) charge ratio of approximately 1:1. The role of liposome in the 1:1 complex may be: (1) to protect DNA from rapid degradation; and (2) to sustain release of DNA at the injection site. Our experiment demonstrated that in the presence of fetal calf serum, the E1A-liposome complex of 1:1 is more resistant to DNA degradation than naked E1A DNA (data not shown). It was shown that free DNA could be transferred to tumors induced by BL6 melanoma tumor cells through intratumor injection. 37 In our transfection experiment, we observed that free lacZ DNA mediated a low level of cell transfection. However, this efficacy is not sufficient to mediate tumor suppression activity of E1A in the i.p. ovarian cancer model. 15 We showed in Figure 2a that the E1A-liposome complex significantly prolonged tumor-bearing mouse survival. The 1 year survival rate of mice administered E1A-liposome at the 13:1 ratio was different from that shown in the previous publication, which demonstrated a 70% survival rate. 15 In the experiment presented here, the weekly injection of E1A-liposome lasted for approximately 4 months, while in the previous experiment, the mice were treated weekly with E1A-liposome complex for 7 months. The difference in the survival rates between these two experiments thus suggests that longer duration of treatment may result in a more appreciable therapeutic efficacy.
While investigating the tumor suppression effects of E1A gene on human cancer cells, we should always be aware that E1A is a multi-functional protein that may interact with a number of cellular proteins and thus could induce potential side-effects in a gene therapy setting. For instance, binding of E1A to pRB family members was thought to inactivate the pRB family and might therefore contribute to the transformation process. CR2 domain of E1A is known to be required for this interaction. 38, 39 In addition, the CR3 domain is involved in transcription activation. The CR3 domain consists of two distinct activities: the N-terminal part is a strong transcription activator and interacts with TATA-binding protein TFIID;
28,40 the C-terminal portion has a promoter binding function which is required to direct the E1A protein to some natural targets, such as the ATF-2.
41 CR3 thus activates transcription by forming an adapter mediating the interaction between the sequence-specific DNA binding transcription factor and the TATA box-binding protein.
Our laboratory has demonstrated that neither the CR2 nor the CR3 domain is required for E1A-mediated repression of HER-2/neu. 31 Deletion of these domains from the E1A gene should help to minimize the cellular effects and increase the specificity of targeting HER-2/neu. As shown in this study, the therapeutic efficacy of mini-E1A in which both CR2 and CR3 domains are deleted, is comparable with that of wild-type E1A in a gene therapy setting. Therefore, the results suggest that mini-E1A may serve as a safer therapeutic agent for targeting HER-2/neu-overexpressing cancer cells.
The E1A DNA was detected in the lungs and kidneys of treated mice and was likely to be integrated into mouse chromosome. Therefore, potential mutation caused by chromosome integration in those two organs is possible. However, PCR is extraordinarily sensitive and in our experimental condition it picks up one copy of E1A gene in more than 10 3 cells (data not shown). It is also worthwhile mentioning that virtually all the anticancer drugs used in clinical situations induce mutations in cells and the extremely poor prognosis of HER-2/neu-overexpressing cancers has made this type of cancer a terminal disease. [4] [5] [6] [7] 42 The possibility that a small fraction of E1A DNA may be integrated into the lungs and kidney is something one needs to be aware of, but it does not exclude this method from being used as an anticancer agent. One of the most encouraging results in the current studies in that E1A gene is undetectable in the cells of mouse reproductive organs even by sensitive PCR techniques. The results suggest that the administration of E1A-liposome complex under the protocol we used is unlikely to cause genetic defects in the patients' progeny. This result should help in lessening concerns about transmission of E1A gene into F1 offspring in this protocol.
Materials and methods
Orthotopic ovarian cancer nude mouse model Four-to six-week-old athymic female homozygous nu/nu mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN, USA) and were cared for and used in accordance with institutional guidelines. Mice were housed for 1-2 weeks, and each mouse considered healthy was injected with 2 × 10 6 SKOV-3.ip1 cells i.p. in aseptic conditions as described elsewhere. 15 Liposome-mediated in vivo gene transfer For measuring the in vivo transfection efficiency, groups of five female nu/nu mice were injected i.p. with 2 × 10 6 SKOV-3.ip1 cells. Six weeks later, each mouse was injected i.p. daily for 3 consecutive days with a complex of 15 g pCHC-␤-gal DNA 32 and liposome (from R Gene Therapeutics) in different lipid:DNA ratios. The mice were killed and protein lysate was extracted from tumor nodules for further analysis of the ␤-galactosidase enzymatic activity. Imprints of the tumors were made by placing the cross-section of the tissue on to the slides. The multiple layer tumor cells attached to the slides were fixed for further X-gal staining.
To test the therapeutic effects of the E1A-liposome complex of different lipid:DNA ratios (or the mini-E1A-liposome complex) on human ovarian cancer cells, the mice that had developed a tumor 5 days after i.p. ONPG analysis and X-gal staining For X-gal staining, the tumor imprints on the slides were fixed for 5 min with a solution containing 0.05% glutaraldehyde and 2% formaldehyde and then washed three times with PBS and stained at room temperature for 2 h with a solution of PBS containing 1 mg/ml X-gal, 5 mm potassium ferricyanide, 5 mm potassium ferrocyanide and 2 mm MgCl 2 .
To assay for ␤-galactosidase activity in tumor cells, protein extracts were made as follows: tumor tissues were homogenized in the presence of PBS on ice, frozen and thawed three times, then centrifuged to obtain the supernatant.
Cell protein lysates were assayed in a reaction mixture containing 1 mm of MgCl 2 , 45 mm of ␤-mercaptoethanol, and 0.88 mg/ml ONPG and incubated at 37°C until yellow color developed. Reactions were stopped by addition of 1 m Na 2 CO 3 , and OD 420 was measured.
Detection of DNA
To determine the presence of E1A DNA in the cells of treated mouse organs, PCR was performed. Mice that had survived for 1. years after E1A treatment was stopped, were killed. The organs, including the uterus, ovary of both sides, liver, lung, spleen. kidney, heart and brain were collected, and DNA was extracted with DNAzol (Molecular Research Center, Cincinnati, OH, USA).
For PCR analysis, 0.5 g of total DNA from each organ was added to a PCR reaction mix containing 1 × Taq polymerase reaction buffer, 200 m dNTPs (dATP, dCTP, dGTP and dTTP), 2 units of Taq polymerase (Boehringer Mannheim, Indianapolis, IN, USA) and 20 pmols each of primers specific to the Ad 5 E1A intron 1 region (5Ј-CGGGATCCCCACCATGAGACATATTATC TGCCACG-3Ј; 5Ј-CGGAATTCTTACTCGAGGTCAA TCCCTTCCTGCACC-3Ј), and to the mouse genomic growth hormone sequence 33 (5ЈTTCGAGCGTGCCTACA TTCC3Ј; 5ЈAAGCGGCGACACTTCATGAC3Ј). Amplification was carried out for 30 cycles in a Perkin Elmer DNA Cycler 480 (Branchburg, NJ, USA) using the following program: denaturing at 94°C for 1 min, annealing at 55°C for 1 min, and extending the primer at 72°C for 1 min. A 15-l sample of each PCR reaction mix was analyzed by running on 1% of agarose gel. Another pair of primers that amplify DNA from the Ad 5 E1A intron 2 region (5ЈCGGGATCCCCACCATGCTCGAGCCTGAGC CTGAGCCCGA3Ј; 5ЈCGGAATTCTTATGGCCTGGGG CGTTTA3Ј) was used in the PCR reaction to confirm the result.
Statistical analysis
Statistical evaluation was performed using the two-tailed Student's t test. A P value of Ͻ0.05 was considered as indicating statistical significance. 
